Chargement en cours...
Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
PURPOSE: Survival of platinum-resistant ovarian cancer (PROC) patients is significantly shortened to around 12 months. Anlotinib is a new multi-target tyrosine kinase inhibitor. The goal of this study is to evaluate the efficacy and safety of anlotinib in PROC patients. PATIENTS AND METHODS: PROC pa...
Enregistré dans:
| Publié dans: | Onco Targets Ther |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7547134/ https://ncbi.nlm.nih.gov/pubmed/33116571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S268613 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|